Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

NCT01052701 | Completed Phase 1 Results

• 1 other identifier: NA_00023807
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

This research is being done to find out whether abacavir (Ziagen®) lowers the levels of ribavirin (Ribapak®) in the body of persons taking these two drugs.

Conditions

Hepatitis C; HIV

Outcome Measures

Primary Outcomes (1)

• Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations

  Ribavirin Triphosphate (RBV-TP) intracellular concentrations.

  Day 56

Secondary Outcomes (1)

• Plasma RBV Trough Concentrations

  Day 56

Study Arms (2)

Ribavirin plus Abacavir

ACTIVE COMPARATOR

Ribavirin plus Abacavir Administration intervention

Drug: Ribavirin plus Abacavir (ABC)

Ribavirin alone

ACTIVE COMPARATOR

Ribavirin alone administration

Drug: Ribavirin

Interventions

Ribavirin DRUG

Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg) OR Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)

Also known as: Ribavirin (RBV)

Ribavirin alone

Ribavirin plus Abacavir (ABC) DRUG

Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg) OR Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg) Plus Daily Abacavir 300 mg orally every 12 hours

Also known as: RBV + ABC

Ribavirin plus Abacavir

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Hepatitis C Virus (HCV) -monoinfected subjects who either successfully completed (defined as cured) or previously failed RBV-based therapy for hepatitis C infection, and are currently not receiving therapy for hepatitis C; at least 18-64 years of age. HCV cure is defined as a sustained undetectable viral response at 24 weeks post treatment.
• Females who are not of reproductive potential (defined as women who have been postmenopausal for at least 24 consecutive months or who have undergone hysterectomy, bilateral oophorectomy, or bilateral tubal ligation.
• Negative serum β- human chorionic gonadotropin (HCG)
• Negative HIV-1 serology documented by any licensed Enzyme-linked immunoassay (ELISA) test kit within 30 days prior to study entry.
• Positive HCV antibody documented within 30 days prior to study entry.
• Negative Human Leukocyte Antigen (HLA)-B\*5701 test documented within 30 days prior to study entry.
• Ability and willingness of subject to provide a signed informed consent and comply with study requirements.
• All subjects must not participate in a conception process (e.g., active attempt to impregnate, sperm donation, in vitro fertilization). If participating in sexual activity that could lead to pregnancy, male subjects must take every precaution to avoid risk of pregnancy for their female partners by using reliable contraception (condom) while receiving study therapy and for 6 months following permanent discontinuation of study therapy. Subjects will also be instructed to counsel their female partners regarding fetal risk and need for appropriate contraception (e.g., hormonal, barrier) so as a secondary effort to prevent pregnancy even though the female partners will not be study participants.
• Estimated creatinine clearance ≥50 mL/minute, within 30 days prior to study entry
• Laboratory values obtained within 30 days prior to study entry:
• Hgb within the normal limits as defined by the reporting laboratory
• Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), and alkaline phosphatase \>5 x upper limit of normal (ULN) as defined by the reporting laboratory.
• Direct bilirubin ≤1.5 x ULN as defined by the reporting laboratory.
• Follicle Stimulate Hormone (FSH) measurement elevated into the menopausal range for females who report being postmenopausal for at least 24 consecutive months is required at screening for all female subjects.
• Subject has not consumed alcohol in the 48 hours prior to the administration of study drugs.

You may not qualify if:

• As determined by the investigator, a significant active or previous history of cardiovascular, renal, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease (s). This inclusive of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, any chronic gastrointestinal condition that may affect drug absorption. History of chronic or acute medical condition that in the opinion of the investigator would jeopardize safety of subjects participating in this study. Any other medical or psychological condition that might, in the opinion of the site investigator, interfere with participation in the study or put subjects at undue risk.
• History of anemia, hemoglobinopathy or any other cause of or tendency to hemolysis.
• History of RBV-induced anemia that required dose reduction or discontinuation of RBV therapy while receiving treatment for hepatitis C infection in the past. Patients who required treatment with erythropoietin or blood transfusion for the management of RBV-associated anemia will be excluded from participating in the study.
• Use of prescription or over-the-counter medications, including herbal products, within 30 days prior to study entry that in the opinion of the investigator would preclude study participation.
• Pregnant women or men with a pregnant female partner.
• Breast feeding
• Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements, and/or currently receiving methadone replacement therapy for the treatment of substance abuse.
• Inability of abstaining from alcohol-containing beverages for the duration of the study.
• Hospitalization or therapy for serious illness within 30 days prior to study entry as judged by the investigator.
• Known or suspected hypersensitivity reaction to study drugs or their formulations.
• Participation in any investigational drug study within 30 days prior to study entry.
• Active or history of gout disease.

Sponsors & Collaborators

• Johns Hopkins University: lead
• GlaxoSmithKline: collaborator
• University of Colorado, Denver: collaborator

Study Sites (1)

Johns Hopkins Drug Development Unit

Baltimore, Maryland, 21287, United States

Location

Related Publications (1)

• Fuchs EJ, Kiser JJ, Hendrix CW, Sulkowski M, Radebaugh C, Bushman L, Ray ML, Andrade A. Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. J Antimicrob Chemother. 2016 Jun;71(6):1597-600. doi: 10.1093/jac/dkw009. Epub 2016 Feb 10.

  PMID: 26869690 DERIVED

MeSH Terms

Conditions

Hepatitis C

Interventions

Ribavirin; abacavir

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis; Liver Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Ribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Results Point of Contact

• Title: Associate Director, Drug Development Unit
• Organization: Johns Hopkins School of Medicine

ejfuchs@jhmi.edu

(410) 614-8762

Study Officials

• Adriana Andrade, MD

  Johns Hopkins University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 19, 2010
• First Posted: January 20, 2010
• Study Start: December 1, 2009
• Primary Completion: September 1, 2012
• Study Completion: December 1, 2012
• Last Updated: May 1, 2017
• Results First Posted: April 27, 2017

Record last verified: 2017-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)